Specific Autoantibody Testing in Patients With Interstitial Lung Disease
The purpose of this study is to evaluate the clinical utility of specific autoantibody testing in unmasking an underlying connective tissue disorder in patients who present with interstitial lung disease and found to have weak positive ANA (1:400 titre) with no overt connective tissue disease manifestations OR borderline/negative ANA with some clinical suggestion of connective tissue disease.
Interstitial Lung Disease
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||To Evaluate the Clinical Utility of Specific Autoantibody Testing in Patients With Interstitial Lung Disease|
- Clinical utility of specific autoantibody testing [ Time Frame: 3 months ] [ Designated as safety issue: No ]Utility of specific autoantibodies to diagnose underlying connective tissue disease in patients presenting with interstitial lung disease who do not demonstrate overt clinical manifestations of connective tissue disease and our current available autoantibody screen does not detect all potential autoantibodies present.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||April 2017|
|Estimated Primary Completion Date:||April 2017 (Final data collection date for primary outcome measure)|
It has been well established that patients with connective tissue disease associated interstitial lung disease respond better to immunosuppressive therapy, and have a better outcome compared to patients with idiopathic interstitial pneumonias. This makes it imperative to identify this group of patients for management and prognostication. Unfortunately some of these patients do not demonstrate overt clinical manifestations of connective tissue disease and our current available autoantibody screen does not detect all potential autoantibodies present. We would like to test for specific autoantibodies in this group of patients to evaluate its clinical utility in identifying covert connective tissue diseases associated with interstitial lung disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01600352
|Contact: Su Ying Low, BMBCh||+65 email@example.com|
|Contact: Andrea Low, MBBS||+65 firstname.lastname@example.org|
|Singapore General Hospital||Recruiting|
|Singapore, Singapore, 169608|
|Principal Investigator: Su Ying Low, BMBCh|
|Principal Investigator:||Su Ying Low, BMBCh||Singapore General Hospital|